Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07563829Phase 1Not Yet Recruiting

NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

Role: lead

NCT06240728Phase 1Recruiting

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

Role: lead

NCT05958199Phase 1Suspended

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Role: lead

All 3 trials loaded